{"id":395004,"date":"2020-12-08T06:03:29","date_gmt":"2020-12-08T11:03:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=395004"},"modified":"2020-12-08T06:03:29","modified_gmt":"2020-12-08T11:03:29","slug":"axsome-therapeutics-announces-positive-results-from-the-comet-si-trial-of-axs-05-in-patients-with-major-depressive-disorder-who-have-suicidal-ideation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/axsome-therapeutics-announces-positive-results-from-the-comet-si-trial-of-axs-05-in-patients-with-major-depressive-disorder-who-have-suicidal-ideation\/","title":{"rendered":"Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation"},"content":{"rendered":"
\n

\n 68<\/em>
\n % reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4<\/em>\n <\/p>\n

\n R<\/em>
\n esolution of suicidal ideation achieved <\/em>
\n by<\/em>
\n 60<\/em>
\n % of patients <\/em>
\n by <\/em>
\n Week 1<\/em>
\n , and 78% by Week 4<\/em>\n <\/p>\n

\n Effect<\/em>
\n s<\/em>
\n consistent with new integrated data from <\/em>
\n AXS-05 <\/em>
\n controlled trials demonstrating reduction in <\/em>
\n MADRS Suicidal<\/em>
\n ity<\/em>
\n Item score <\/em>
\n versus control, <\/em>
\n at<\/em>
\n Week 1 (p=0.001)<\/em>\n <\/p>\n

\n Rapid and s<\/em>
\n ubstantial improvement in <\/em>
\n functioning <\/em>
\n achieved by <\/em>
\n 51<\/em>
\n % of patients at Week <\/em>
\n 1<\/em>
\n and <\/em>
\n 77<\/em>
\n % <\/em>
\n of patients <\/em>
\n at Week 6 <\/em>
\n (<\/em>
\n S<\/em>
\n heehan Disability Scale)<\/em>\n <\/p>\n

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced positive results from the open-label Phase 2 COMET-SI trial of AXS-05 in patients with major depressive disorder (MDD) who have suicidal ideation (SI). Patients treated with AXS-05 experienced rapid reduction of suicidal ideation, rapid functional improvement, and rapid, substantial, and durable improvements in overall depressive symptoms. The COMET-SI trial evaluated 37 patients with suicidal ideation, defined as a score of \u22653 on the Suicidality Item of the Montgomery-\u00c5sberg Depression Rating Scale (MADRS-SI), at baseline. Patients were treated with AXS-05 (45 mg dextromethorphan-105 mg bupropion modulated delivery tablet) twice daily for up to 12 months. AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.<\/p>\n

A rapid reduction in suicidal ideation was observed with AXS-05 treatment, as demonstrated by reductions in the MADRS-SI score of 67.6% by Week 1, the earliest time point measured, 73.5% by Week 2, and 82.4% by Week 4. Resolution of suicidal ideation with AXS-05 treatment was achieved by 60.0% of patients by Week 1, 68.8% by Week 2, and 77.8% of patients by Week 4. Resolution was defined as a MADRS-SI score of 0 or 1 on a 0 to 6 scale.<\/p>\n

The effect of AXS-05 on suicidal ideation in the open-label COMET-SI trial is consistent with new controlled data from the previously completed placebo-controlled GEMINI and active-controlled ASCEND trials of AXS-05 in the treatment of MDD. Integrated analysis from these trials demonstrated rapid reduction in MADRS-SI scores with AXS-05 compared to placebo or active control, which was statistically significant at Week 1, the earliest time point assessed (p=0.001 versus control).<\/p>\n

The improvement in suicidal ideation with AXS-05 treatment in the COMET-SI trial was accompanied by rapid, substantial, and durable improvement in functional impairment, as measured by the Sheehan Disability Scale (SDS). The SDS is a patient-rated scale designed to assess function in work, social life, and family life, and is among the most commonly used function scales in depression clinical trials. Functional response on the SDS (defined as a total score of \u226412) was achieved after treatment with AXS-05 by 51.4% of patients at Week 1, 62.5% of patients at Week 2, and 76.9% of patients at Week\u00a06.<\/p>\n

Clinicians reported rapid, substantial, and durable global improvement in depression, measured by the Clinical Global Impression of Improvement (CGI-I) scale, in patients treated with AXS-05 in the COMET-SI trial. Marked or moderate improvement in depressive symptoms was achieved after treatment with AXS-05 by 40.0% of patients at Week 1, 59.4% of patients at Week 2, and 69.2% of patients at Week\u00a06.<\/p>\n

AXS-05 treatment in the COMET-SI trial also resulted in rapid, substantial, and durable improvement in depressive symptoms as measured by the MADRS total score. Patients experienced a mean reduction from baseline in the MADRS total score of 12.9 points at Week 1, 17.8 points at Week 2, and 22.8 points at Week 6. Clinical response on the MADRS (defined as \u226550% reduction in total score from baseline) was achieved after treatment with AXS-05 by 25.7% of patients at Week 1, 46.9% of patients at Week 2, and 69.2% of patients at Week 6. Remission from depression (defined as MADRS \u226410) was achieved after treatment with AXS-05 by 11.4% of patients at Week 1, 28.1% of patients at Week 2, and 50.0% of patients at Week 6.<\/p>\n

\u201cThese early data are the first for AXS-05 in major depressive disorder patients with suicidal ideation, and highlight the rapid onset of action of AXS-05, observed by the first week, on clinically important measures in this serious condition\u201d said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. \u201cThe results of the COMET-SI trial suggest that AXS-05, as an oral NMDA receptor antagonist, may provide unique benefits to patients by potentially rapidly and durably improving not only suicidal thoughts but also functional impairment associated with depression. These positive effects expand on and are consistent with the differentiated clinical profile of AXS-05 observed in our completed controlled trials in patients with major depressive disorder.\u201d<\/p>\n

AXS-05 was well tolerated in the COMET trial. The safety profile observed was consistent with what was previously reported in controlled trials of AXS-05 in MDD, with the most commonly reported adverse events being dizziness, nausea, headache, dry mouth, and decreased appetite.<\/p>\n

\n COMET-<\/strong>
\n SI<\/strong>
\n Results<\/strong>
\n Summary<\/strong>\n <\/p>\n

A total of 37 patients with major depressive disorder (MDD) who had suicidal ideation at baseline were treated with AXS-05 (45 mg dextromethorphan-105 mg bupropion modulated delivery tablet) twice daily for up to 12 months. Suicidal ideation was defined as a score of \u22653 on the Suicidality Item of the Montgomery- \u00c5sberg Depression Rating Scale (MADRS-SI) on a 0 to 6 scale. Topline results are summarized below:<\/p>\n